Lisata Therapeutics Forms Strategic Alliance with Catalent for ADC Development

October 10, 2025 - 03:01

Lisata Therapeutics, Inc. has announced the initiation of a global product license agreement with Catalent, Inc. This collaboration allows Catalent to integrate Lisata’s innovative certepetide into antibody-drug conjugates (ADCs) utilizing Catalent’s advanced SMARTag technology platform. This partnership highlights the adaptability of certepetide and strategically positions Lisata’s technology within a prominent ADC framework.

The agreement is expected to enhance the development of novel therapeutics, combining Lisata's unique peptide with Catalent's cutting-edge technology. By leveraging each other's strengths, both companies aim to accelerate the creation of targeted cancer therapies that could significantly improve patient outcomes.

Lisata’s commitment to advancing its therapeutic offerings is underscored by this collaboration, which not only validates the potential of certepetide but also underscores the growing importance of ADCs in oncology. As both companies move forward, the partnership is anticipated to pave the way for innovative treatments in the fight against cancer.